항암 및 항암보조제
Oncology Portal | News
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer
https://www.annalsofoncology.org/article/S0923-7534(20)39833-1/fulltext
Neratinib approved in China for early breast cancer
Expert opinion on FDA approval of neratinib for metastatic breast cancer
FDA Approves Neratinib Combo for HER2+ Breast Cancer
https://www.onclive.com/web-exclusives/fda-approves-neratinib-combo-for-her2-breast-cancer
Impact of Neratinib on CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer: Analysis of Data From Phase II/III Trials
Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer
Neratinib Approved in Canada for Early-Stage HER2+ Breast Cancer
Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer
Copyright 2020 - BIXINK | Terms of Use | Contact
서울특별시 강남구 논현로 561 6층 [06125]
6F, 561 Nonhyeon-ro, Gangnam-gu, Seoul 06125, Republic of Korea